Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 18, 2008 - Issue 6
Submit an article Journal homepage
33
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Anti-apoptotic agents for the treatment of vascular disease

Alexandros Briasoulis Athens University Medical School, First Cardiology Unit, Hippokration Hospital, 69 S. Karagiorga Street, Athens 16675, Greece +30 210 7782446; +30 210 7784590; [email protected]
, MD,
Dimitris Tousoulis Athens University Medical School, First Cardiology Unit, Hippokration Hospital, 69 S. Karagiorga Street, Athens 16675, Greece +30 210 7782446; +30 210 7784590; [email protected]
, MD PhD FACC &
Christodoulos Stefanadis Athens University Medical School, First Cardiology Unit, Hippokration Hospital, 69 S. Karagiorga Street, Athens 16675, Greece +30 210 7782446; +30 210 7784590; [email protected]
, MD FACC
Pages 569-580 | Published online: 26 May 2008

Bibliography

  • Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-74
  • Kockx MM. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 1998;18:1519-22
  • Kerr JF. Shrinkage necrosis: a distinct mode of cellular death. J Pathol 1971;105(1):13-20
  • Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000;407(6805):784-8
  • Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8
  • Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12
  • Boldin MP, Varfolomeev EE, Pancer Z, et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795-8
  • Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996;85:803-15
  • Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27
  • Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579-88
  • Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome C release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90
  • Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501
  • Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004;1644:83-94
  • Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C. Cell 1996;86:147-57
  • Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42
  • Suzuki Y, Imai Y, Nakayama H, et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001;8:613-21
  • Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6
  • Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001;412:95-9
  • Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome C from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6
  • Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608
  • Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89
  • Bratton SB, Walker G, Srinivasula SM, et al. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J 2001;20:998-1009
  • Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome C by direct inhibition of distinct caspases. EMBO J 1998;17:2215-23
  • Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53
  • Faccio L, Fusco C, Chen A, et al. Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 2000;275:2581-8
  • Lee T, Chau L. Fas/Fas ligand-mediated death pathway is involved in oxLDL-induced apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001;280:C709-18
  • Norata GD, Tonti L, Roma P, Catapano AL. Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: possible role of oxidised LDL. Nutr Metab Cardiovasc Dis 2002;12:297-305
  • Mallat Z, Heymes C, Ohan J, et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999;19:611-6
  • Fadok VA, Savill JS, Haslett C, et al. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol 1992;149:4029-35
  • Miwa K, Asano M, Horai R, et al. Caspase 1-independent IL-1b release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998;4:1287-92
  • Schaub FJ, Han DK, Conrad Liles W, et al. Fas/ FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 2000;6:790-6
  • Chang MK, Bergmark C, Laurila A, et al. Monoclonal antibodies against oxidized low density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 1999;96:6353-8
  • Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26
  • Caplan BA, Schwartz CJ. Increased endothelial cell turnover in areas of in vivo Evans Blue uptake in the pig aorta. Atherosclerosis 1993;17:401-17
  • Davies PF, Remuzzi A, Gordon EJ, et al. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci USA 1986;83:2114-7
  • Tricot O, Mallat Z, Heymes C, et al. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 2000;101:2450-3
  • Urbich C, Walter DH, Zeiher AM, Dimmeler S. Laminar shear stress upregulates integrin expression: role in endothelial cell adhesion and apoptosis. Circ Res 2000;87:683-9
  • Ilic D, Almeida EA, Schlaepfer DD, et al. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 1998;143:547-60
  • Bartling B, Tostlebe H, Darmer D, et al. Shear stress-dependent expression of apoptosis-regulating genes in endothelial cells. Biochem Biophys Res Commun 2000;278:740-6
  • Garcia-Cardena G, Comander J, Anderson KR, et al. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001;98:4478-85
  • Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1999;89:2429-42
  • Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 1999;93:3831-8
  • Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999;43:562-71
  • Betteridge DJ. What is oxidative stress? Metab Clin Exp 2000;49:3-8
  • Napoli C, De Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem 2001;82:674-82
  • Abdu TA, Elhadd T, Pfeifer M, Clayton RN. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001;12:257-65
  • Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501
  • Chen CH, Jiang T, Yang JH, et al. Low density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003;107:2102-8
  • Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem 1998;273:33103-6
  • Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest 1998;102:1682-9
  • Polunovsky VA, Wendt CH, Ingbar DH, et al. Induction of endothelial cell apoptosis by TNF alpha: modulation by inhibitors of protein synthesis. Exp Cell Res 1994;214:584-94
  • Ho FM, Liu SH, Liau CS, et al. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 2000;101:2618-24
  • Li D, Yang B, Philips MI, Mehta JL. Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation. Am J Physiol 1999;276:786-92
  • Romeo F, Li D, Shi M, Mehta JL. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 2000;45:788-94
  • Perlman H, Maillard L, Krasinski K, Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 1997;95:981-7
  • Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005;25:2255-64
  • Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002;110:905-11
  • Tabas I. Apoptosis and plaque destabilization: the role of macrophage apoptosis induced by cholesterol. Cell Death Differ 2004;11:S12-6
  • Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005;178:359-63
  • Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005;91:27-31
  • Tousoulis D, Antoniades C, Katsi V, et al. The impact of early administration of low dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. Int J Cardiol 2006;109:48-52
  • Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10
  • Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-71
  • Bernini F, Didoni G, Bonfadini G, et al. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993;104:19-26
  • Vamvakopoulos JE, Green C. HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary humanmonocytes: a potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord 2003;3:6
  • Indolfi C, Di Lorenzo E, Rapacciuolo A, et al. 8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J Am Coll Cardiol 2000;36:288-93
  • Erl W, Hristov M, Neureuter M, et al. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 2003;169:251-8
  • Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500
  • Baetta R, Donetti E, Comparato C, et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 1997;36:115-21
  • Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis. Part I. oxidative stress and atherogenesis. Circulation 2002;105:393-6
  • Faggiotto A, Paoletti R. State-of-the-art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999;34:987-96
  • Trevelyan J, Needham EW, Morris A, Mattu RK. Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. Heart 2005;91:1053-7
  • Erzen B, Gradisek P, Poredos P, Sabovic M. Treatment of essential arterial hypertension with enalapril does not result in normalization of endothelial dysfunction of the conduit arteries. Angiology 2006;57:187-92
  • Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metabol 2003;88:4496-501
  • Siegert A, Ritz E, Orth S, Wagner J. Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-beta1 in vascular smooth muscle. J Mol Med 1999;77:437-45
  • Bascands JL, Girolami JP, Troly M et al. Angiotensin II induces phenotype-dependent apoptosis in vascular smooth muscle cells. Hypertension 2001;38:1294-9
  • Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappa B and stimulates I-kappa-B in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-65
  • Ghanim H, Mohanty P, Aljada A, et al. Insulin reduces the pro-inflammatory transcription factor, activation protein-1 (AP-1), in mononuclear cells (MNC) and plasma matrix metalloproteinase-9 (MMP-9) concentration. Diabetes 2001;50(Suppl 2):A408
  • Aljada A, Ghanim H, Mohanty P, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002;87:1419-22
  • Dandona P, Aljada A, Mohanty P, et al. Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 2003;26:3310-4
  • Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001;89:1191-8
  • Chaudhuri A, Janicke D, Wilson MF, et al. Antiinflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004;109:849-54
  • Shamir R, Shehadeh N, Rosenblat M, et al. Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:104-10
  • Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35
  • Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappa B and stimulation of inhibitor kappa B by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-12
  • Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappa B suppressive and inhibitor-kappa B stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 2001;86:3250-6
  • Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003;52:173-80
  • Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001;21:372-7
  • Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:365-71
  • Hennuyer N, Tailleux A, Torpier G, et al. PPAR-alpha, but not PPAR-gamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1897-902
  • Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
  • Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. J Am Med Assoc 2007;298:1180-8
  • Thorp E, Kuriakose G, Shah YM, et al. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation 2007;116:2182-90
  • Tousoulis D, Antoniades C, Tentolouris C, et al. L-arginine in cardiovascular disease: dream or reality? Vasc Med 2002;3:203-11
  • Tentolouris C, Tousoulis D, Goumas G, et al. L-arginine in coronary atherosclerosis. Int J Cardiol 2000;75:123-8
  • Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002;53:515-24
  • Tousoulis D, Antoniades C, Koumallos N. Novel therapies targeting vascular endothelium. Endothelium 2006;13:411-21
  • Lerman A, Burnett JC Jr, Higano ST, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-8
  • Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-36
  • Tousoulis D, Antoniades C, Tentolouris, et al. Antioxidant vitamins C and E administration in smokers: effects on endothelial function and adhesion molecules. Atherosclerosis 2003;170:263-9
  • Antoniades C, Tousoulis D, Tentolouris C, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemostasis 2003;89:990-5
  • GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55
  • HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9
  • HPS Study Investigators. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002;360:23-33
  • Levy AP. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharm Ther 2006;112:501-12
  • Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both Type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective, double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008;28:341-7
  • Pfuetze KD, Dujovne CA. Probucol. Curr Atheroscler Rep 2000;2:47-57
  • Kunsch C, Luchoomun J, Grey JY, et al. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther 2004;308:820-9
  • Luyendyk JP, Piper JD, Tencati M, et al. A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases. Arterioscler Thromb Vasc Biol 2007;27:1857-63
  • Sundell CL, Somers PK, Meng CQ, et al. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther 2003;305:1116-23
  • Tardif JC, Gregoire J, L'Allier PL, et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2008;197(1):480-6
  • Teede HJ, Liang YL, Kotsopoulos D, et al. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol 2001;55:673-82
  • De Kleijn MJ, Wilmink HW, Bots ML, et al. Hormone replacement therapy and endothelial function. Results of randomized control trial in healthy post menopausal women. Atherosclerosis 2001;159:357-65
  • Wakatsuki A, Okatani Y, Ikenoue N, et al. Effects of medroxyprogesterone acetate on endothelial-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001;104:1773-8
  • Kelemen M, Vaidya D, Waters DD, et al. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis 2005;179:193-200
  • Yeboah J, Reboussin DM, Waters D, et al. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2007;153:439-44
  • Post WG, Goldschmidt-Clemont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985-91
  • Xiong Y, Yaun LW, Deng HW, et al. Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats. Clin Exp Pharmacol Physiol 2001;28:842-7
  • Schulze F, Maas R, Freese R, et al. Determination of reference value for N(G),N(G) dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35:622-6
  • Lenzen H, Tsikar D, Boger RH. Asymmetrical dimethyl-arginine and risk of CHD: the multicenter CARDIAC study. Eur J Clin Pharmacol 2006;62:45-9
  • Cary SP, Winger JA, Marletta MA. Tonic and acute nitric oxide signalling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP and GTP. Proc Natl Acad Sci USA 2005;102:13067-9
  • Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and cardiovascular system. Lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741-53
  • Pollman MJ, Hall JL, Mann MJ, et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998;4:222-7
  • Sata M, Suhara T, Walsh K. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol 2000;20:309-16
  • Sata M, Walsh K. TNF α regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998;4:415-20
  • George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000;9:993-1007
  • George SJ, Lloyd CT, Angelini GD, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000;101:296-304
  • Li Y, Higashi Y, Itabe H, et al. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol 2003;23:2178-84
  • Lee P, Sata M, Lefer DJ, et al. The Fas pathway is a critical mediator of cardiac myocyte death and myocardial infarction during ischemia/reperfusion in vivo. Am J Physiol Heart Circ Physiol 2000;284:H456-63
  • Hochhauser E, Kivity S, Offen D, et al. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol 2003;2846:H2351-9
  • Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 1999;31(9):1709-15
  • Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97(3):276-81
  • Liu HR, Gao E, Hu A, et al. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation 2005;111(1):90-6
  • Tangirala RK, Bischoff ED, Joseph SB, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002;99:11896-901
  • Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006;113:90-7
  • Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-14
  • Bakhutashvili V. US2007123467; 2007
  • Larisch S. CA2552955; 2005
  • Kohler H. WO2006119291; 2006
  • Hla T, Sanchez T, Claffey KP, et al. US2008039530; 2008
  • Geng YJ. WO2006053130; 2006

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.